Maipl Therapeutics is developing novel oral, non-hormonal therapeutics to treat endometriosis, which affects nearly 10% of reproductive-age women. Its innovation focuses on the FP receptor of prostaglandin F2α (PGF2α), which is often elevated in the peritoneal fluid and ectopic tissue of endometriosis patients. Its first-in-class drug candidate MA-4604 is highly selective and potent FP receptor antagonists that have shown promising preclinical results by reducing uterine contractions, intrauterine pressure, lesion size, and associated pain, thereby establishing preclinical Proof of Concept. Maipl's current focus is preclinical studies leading to the Phase 1 trial.

Office Locations

Scarsdale, New York